XOMA to Present at the Cantor Fitzgerald Healthcare Conference 2018 and the 2018 BIO Investor Forum
Cantor Fitzgerald Healthcare Conference2018 on Tuesday, October 2, 2018, at 3:25PM ETin New York, New York; and,
BIO Investor Forumon Wednesday, October 17, 2018, at 10:45AM PTin San Francisco, California.
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees’ may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them. Other potential risks to
Oratorium Group, LLC
KV Consulting & Management
Source: XOMA Corporation